Comparing the New Anti-cancer Drug Eribulin With or Without Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Bladder Cancer

Conditions:   Metastatic Bladder Urothelial Carcinoma;   Refractory Bladder Urothelial Carcinoma;   Stage IV Bladder Cancer AJCC v8;   Stage IVA Bladder Cancer AJCC v8;   Stage IVB Bladder Cancer AJCC v8 Interventions:   Drug: Docetaxel;   Drug: Eribulin Mesylate;   Drug: Gemcitabine Hydrochloride;   Drug: Paclitaxel Sponsor:   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

Bladder cancer (BC) is the 10th most common cancer worldwide. Approximately one quarter of patients with BC have muscle-invasive disease (MIBC). Muscle-invasive disease carries a poor prognosis and choosing the optimal treatment option is critical to improve patients’ outcomes. Ongoing research supports the role of 2-deoxy-2-(18F)fluoro-D-glucose positron emission tomography (18F-FDG PET) in guiding patient-specific management decisions throughout the course of MIBC. As an imaging modality, 18F-FDG PET is acquired simultaneously with either computed tomography (CT) or MRI to offer a hybrid approach combining anatomic...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
We report the ESTRO-ACROP (European Society for Radiotherapy and Oncology - Advisory Committee on Radiation Oncology Practice) recommendations for performing IORT in primary locally advanced rectal cancer. PMID: 33005755 [PubMed]
Source: Clinical Prostate Cancer - Category: Cancer & Oncology Authors: Tags: Clin Transl Radiat Oncol Source Type: research
AbstractA 68-year-old man was diagnosed with non-muscle-invasive bladder cancer and underwent transurethral resection of the bladder tumor (TURBT) in June 2014. The pathological diagnosis was urothelial carcinoma (UC), Grade 2, pT1. He was treated with intravesical bacillus Calmette –Guérin (BCG) instillation after TURBT. In February 2016, he received anti-tuberculosis treatment for systemic BCG infection, and tuberculosis treatment was continued. In September 2018, he presented with bilateral scrotum swelling and underwent bilateral orchiectomy following a diagnosis of anti tuberculotics-resistant epididymiti...
Source: International Cancer Conference Journal - Category: Cancer & Oncology Source Type: research
Treatment options as second-line therapy for advanced ureteral carcinoma are limited, and patients experiencing recurrence after first-line cisplatin-based chemotherapy have a poor prognosis. Recently, the programmed death-1 (PD-1) inhibitor pembrolizumab provided a better survival benefit with a complete response rate (9.2%) for chemoresistatant urothelial carcinoma. However, the dynamic changes of the cancer microenvironment about the cases of complete response are still unknown. We herein report a case of a 57-year-old man who had been diagnosed with localized, non-muscle-invasive bladder cancer (pT1N0M0, high grade), f...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Patients with intermediate or locally advanced rectal carcinoma are treated according to international guidelines with neoadjuvant radiotherapy with or without concurrent chemotherapy followed by total mesorectal excision surgery.[1,2] Neoadjuvant radiotherapy leads to a reduction in local recurrence rate but is still associated with substantial toxicity as large planning volumes are needed to compensate for inter- and intrafraction movement.[3,4] Particularly the mesorectum is a nonstationary structure, with large day-to-day variation as its shape and volume are affected by both bladder and rectal filling.
Source: Radiotherapy and Oncology - Category: Radiology Authors: Tags: Original Article Source Type: research
Authors: Murphy N, Shah P, Shih A, Khalili H, Liew A, Zhu X, Lee A Abstract Single-cell sequencing (SCS) is a powerful new tool that applies Next Generation Sequencing at the cellular level. SCS has revolutionized our understanding of tumor heterogeneity and the tumor microenvironment, immune infiltration, cancer stem cells (CSCs), circulating tumor cells (CTCs), and clonal evolution. The following chapter highlights the current literature on SCS in genitourinary (GU) malignancies and discusses future applications of SCS technology. The renal cell carcinoma (RCC) section highlights the use of SCS in characterizing ...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
CONCLUSIONS: These data show the implementation of immunotherapy as a novel alternative against renal and bladder cancer. The arrival of new agents for advanced urothelial carcinoma should be highlighted, and the efficacy of enzalutamide and apalutamide in de novo metastatic prostate cancer is established. In metastatic CRPC, cabazitaxel and olaparib (targeting mutations) are promising therapeutic options. PMID: 32948345 [PubMed - as supplied by publisher]
Source: Actas Urologicas Espanolas - Category: Urology & Nephrology Authors: Tags: Actas Urol Esp Source Type: research
Authors: Volovat SR, Ciuleanu TE, Koralewski P, Olson JEG, Croitoru A, Koynov K, Stabile S, Cerea G, Osada A, Bobe I, Volovat C Abstract NC-6004 is a nanoparticle developed using micellar technology that can improve release of cisplatin, a standard treatment for many cancer types, and achieve selective distribution to tumors. Here, in the Phase II portion of this study, the activity, safety, tolerability, and effects on quality of life of NC-6004 in combination with gemcitabine was examined in 34 squamous non-small cell lung carcinoma (NSCLC) patients, 50 biliary tract cancer patients, and 13 bladder cancer patient...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Small cell carcinoma of the urinary bladder is a rare subtype (incidence of 1 –9/1,000,000), characterized by an aggressive behavior with early metastasis and poor prognosis. Chemotherapy, radiation, and surgery are the usual treatment options, but to date, no accepted standard treatment exists. Since small cell bladder cancer shares similar clinicopathological features wit h small cell lung cancer, the same type of chemotherapy has been used. Recently, immune checkpoint inhibitors have shown effect in small cell lung cancer, but data regarding small cell bladder cancer is insufficient. Here we present a case where a...
Source: Case Reports in Oncology - Category: Cancer & Oncology Source Type: research
The objective of this review is to summarize the evidence of trimodal therapy for muscle invasive bladder cancer during the past decade and to discuss the future directions of bladder preservation therapy in immuno-oncology era.
Source: Japanese Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
More News: Bladder Cancer | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Docetaxel | Research | Taxotere